B23-Circular Dichroism
|
Xi
Lei
,
Sibo
Peng
,
Nijas
Aliu
,
Rohanah
Hussain
,
Giuliano
Siligardi
,
Tiberiu-Marius
Gianga
,
Xin
Jin
,
Sabrina
Ruggiero
,
Shilpa
Chokshi
,
Luca
Urbani
,
Bernhard F.
Gibbs
,
Elena
Klenova
,
Gurprit S.
Lall
,
Gabriela
Dekany
,
Dietmar
Cholewa
,
Steffen M.
Berger
,
Maryam
Abooali
,
Inna M.
Yasinska
,
Song
Xu
,
Elizaveta
Fasler-Kan
,
Vadim V.
Sumbayev
Diamond Proposal Number(s):
[36941, 38189]
Abstract: Human cancer cells and malignant tumours operate immune evasion machinery, which consists of a set of cross-linked biochemical pathways that suppress the activities of immune cells, such as cytotoxic T cells and natural killer cells. Recent evidence demonstrated that the immune evasion machinery operated by human cancer cells is self-sustaining. However, the mechanisms underlying self-regulation of cancer immune evasion networks remain to be understood. Here we report for the very first time that the cell surface receptor CD44 acts as an enhancer of immune evasion activity in human cancer cells rather than an immune checkpoint per se. Furthermore, upon interaction with galectin-9, CD44 was found to alter cell membrane potential and induce the secretion of TGF-β. Secreted TGF-β displays autocrine and paracrine activities following TGF-β receptor (TGFBR) engagement, which was shown to then activate the Smad3 transcriptional pathway. CD44 complexed to galectin-9 allosterically enhances activity of the TGFBR complex and this was shown to substantially amplify the expression of immune checkpoint proteins crucially associated with suppressing the anti-cancer activities of cytotoxic lymphoid cells. We also demonstrated that this is a fundamental pathway used by human embryos to prevent immune rejection and by innate immune cells to facilitate anti-bacterial innate immune response. Cancer cells and malignant tumours hijack and successfully adapt this fundamental pathway to escape immune surveillance and suppress anti-cancer immune reactions. As such, this autocrine loop allows for the self-regulation of immune evasion networks operated by cancer cells and can be considered as a promising target for highly efficient immunotherapy of cancer.
|
Nov 2026
|
|
I03-Macromolecular Crystallography
I04-Macromolecular Crystallography
|
Abstract: The work investigates the biological characteristics, lipid antigen presentation properties, and T cell recognition mechanisms of CD1c, with the ultimate aim of developing HLA-independent T cell–redirecting therapeutic strategies. By targeting a non-polymorphic molecule with restricted expression in hematological malignancies, the dissertation proposes a strategy that could potentially broaden patient eligibility while reducing the risk of immune escape associated with peptide–HLA variability. In doing so, the thesis bridges fundamental immunological research with translational therapeutic development and contributes meaningfully to the advancement of next-generation engineered T cell therapies.
|
Oct 2026
|
|
I03-Macromolecular Crystallography
|
Dinesh
Chimmanamada
,
Maria-Dorothea
Nastke
,
Archna
Ravi
,
Jacob P.
Matson
,
Alex G.
Batrouni
,
Andressa L.
Mota
,
Pedro N.
Pozo
,
Eric M.
Grund
,
Micholas Dean
Smith
,
Anne-Catherine
Abel
,
Mustafa T.
Kendirli
,
Jeremy C.
Smith
,
Lawrence
Recht
,
Niven R.
Narain
,
Stephane
Gesta
,
Michel O.
Steinmetz
,
Andrea E.
Prota
,
Vivek K.
Vishnudas
Diamond Proposal Number(s):
[34035]
Abstract: The limited number of approved drugs for treatment of brain cancers is very apparent. Temozolomide and Vorasidenib continue to be the only approved brain-permeable, orally available drugs. A novel class of highly brain-penetrant tubulin-binding ligands was discovered through rigorous structure−activity-relationship (SAR) studies. The lead compounds were validated through tubulin polymerization assays and co-crystallization, demonstrating destabilization of microtubules by binding to the colchicine site of tubulin. The ligands maintain core interactions with tubulin like those of colchicine; however, both the tubulin βT7 and αT5 loops adopt flipped conformations compared with the colchicine-bound state. SAR studies revealed high selectivity for substitutions, with a small number of indispensable moieties, and led to the selection of small-molecule compound 40 as the clinical candidate. Compound 40 is highly potent, has high gut and moderate brain permeability, a favorable clearance and cytochrome P450 inhibition/induction profile, and demonstrated activity in models of glioma.
|
Oct 2026
|
|
I24-Microfocus Macromolecular Crystallography
|
Abstract: Glycosphingolipids (GSLs) are essential components of biological membranes, with several functions in both normal physiology and disease pathology. Glycosphingolipids are synthesised by lipid glycosyltransferase enzymes through the sequential addition of sugar groups onto the growing glycan headgroup. Perturbations in GSL biosynthesis can cause severe neurological disease and are implicated in a range of cancers. B4GALNT1 is one such glycosphingolipid biosynthetic enzyme, where loss-of-function results in a complex form of hereditary spastic paraplegia, and its dysregulation is associated with cancer, particularly paediatric neuroblastoma. B4GALNT1 is a key enzyme of ganglioside biosynthesis, a sialylated subclass of GSLs. In this work we present the first experimental structure of a GSL biosynthetic enzyme, namely B4GALNT1. We demonstrate dynamic remodelling of the B4GALNT1 active site upon substrate binding and identify the functional consequence of disease associated mutations. We show that B4GALNT1 possesses hydrophobic surface exposed loops that flank the active site that are essential to B4GALNT1 activity, with mutation of hydrophobic residues to polar resulting in severely ablated activity. Molecular dynamics simulations offered mechanistic insight, providing evidence that these surface exposed loops can insert into lipid bilayers to facilitate binding of the lipid substrate into the active site. We extended this work through further molecular dynamics simulations of predicted structures for other ganglioside synthetic enzymes, that such a mechanism involving membrane insertion loops may be exploited by other GSL biosynthetic enzymes. To step more broadly into the pathological consequence of GSL biosynthesis we developed a suite of computational tools to facilitate gene expression informed metabolic simulations of the GSL biosynthetic network. These tools enable simple and rapid gene knockout simulations whilst also permitting patient or cell-specific simulations of GSL metabolism. Given disrupted GSL metabolism is associated with malignancy in several cancers and the potential mechanistic roles of GSLs in different tumour types, we sought to leverage these tools in a cancer setting. We focused on Lower Grade Glioma (LGG) due to existing evidence for GSL related malignant phenotypes in Glioblastoma Multiforme (GBM) coupled to transcriptional similarities in severe LGG and GBM. We utilised patient specific metabolic simulations to enrich GSL biosynthetic enzyme transcriptomic datasets which were then utilised for training an ensemble-based machine learning model. This approach yielded strong risk-stratification for LGG patients whilst also implicating several biological pathways as potential GSL-related drivers of severity. These included cell motility, division and Wnt signalling. Together this work establishes molecular mechanistic detail on the function of the B4GALNT1 ganglioside biosynthetic enzyme and extends to the in silico modelling of GSL metabolism which was leveraged through machine learning to model survival and make biological insights in LGG.
|
Oct 2026
|
|
I04-Macromolecular Crystallography
|
Diamond Proposal Number(s):
[39391]
Abstract: RING domains catalyse ubiquitination by stabilising a closed conformation of E2-ubiquitin (Ub) conjugates, with TRIpartite Motif (TRIM) proteins representing the largest subfamily of RING-type E3 ligases. TRIM proteins are implicated in many physiological processes and diseases. For example, TRIM8 perturbation has been variously linked to neurodevelopmental defects and several cancer types, attributed to its ubiquitination of a myriad of putative substrates. However, the molecular mechanisms behind these modifications are not yet clear. Here we show that TRIM8 has preferential functionality with the E2 enzyme UBE2N to generate K63-linked poly-ubiquitin chains. By solving the crystal structure of TRIM8 RING bound to a UBE2N-Ub conjugate, we discover that its non-canonical asparagine ‘linchpin’ residue belies this selectivity by failing to form key contacts required to stabilise the closed conformation of other E2 enzymes. These findings not only open the door to exploring the impact of TRIM8-mediated K63 chain formation in health and disease, but also add to a growing appreciation of the specificities of RING domain catalytic activity.
|
Oct 2026
|
|
I03-Macromolecular Crystallography
|
Jayden R.
Sterling
,
Jacinda R.
Holtsmark
,
George L.
Joun
,
Matthew S.
Graus
,
Tian Y.
Du
,
Mani
Kuchibhotla
,
Terrance G.
Johns
,
Antoine
Deweck
,
Lipin
Loo
,
G. Gregory
Neely
,
Karen
Tran
,
Chloe
Shard
,
Guillermo A.
Gomez
,
Ashwini
Patil
,
Diana D.
Shi
,
Julie-Aurore
Losman
,
Angus J.
Saxton
,
Jennifer R.
Baker
,
Zhihe
Lei
,
Matthew T. O.
Holland
,
Paul E.
Brennan
,
Mathias
Francois
,
Andreas
Kraemer
,
Susanne
Mueller
,
Yuchen
Feng
,
Paul
Workman
,
Lenka
Munoz
Open Access
Abstract: Histone lysine demethylase 4 (KDM4) enzymes are frequently overexpressed in cancer and are considered to be promising therapeutic targets. QC6352, which is widely used as a best-in-class KDM4 chemical probe, shows potent antitumor activity across cancer models. Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition. Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity. Uridine supplementation and expression of an inhibitor-resistant DHODH mutant fully abrogate growth inhibition, whereas the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352. These findings establish QC6352 and zavondemstat as dual KDM4–DHODH inhibitors and identify DHODH inhibition as the dominant driver of their antiglioblastoma efficacy, as well as demonstrating the need for orthogonal chemical probes to accurately define drug mechanisms in cells.
|
Oct 2026
|
|
B21-High Throughput SAXS
|
Francesco
Rinaldi
,
Pedro
Franco
,
Marina
Veronesi
,
Elisa
Romeo
,
Veronica
Bresciani
,
Giulia
Varignani
,
Federico
Catalano
,
Mattia
Bernetti
,
Matteo
Masetti
,
Julian D.
Langer
,
Stefania
Girotto
,
Andrea
Cavalli
Diamond Proposal Number(s):
[37027]
Open Access
Abstract: Homologous recombination (HR) is a critical repair pathway involving numerous proteins that ensure error-free DNA double-strand breaks (DSBs) repair. Dysfunction in HR components can compromise genome integrity. Despite advances, many aspects of HR remain poorly understood. Notably, even one of the earliest identified and most critical interactions, between RAD51 and BRCA2, remains incompletely characterized, mainly due to the lack of structural data. This study presents a comprehensive biophysical analysis of the RAD51–BRC repeats interaction, integrating computational and experimental approaches. Starting with assessing the correlation between the binding affinities of individual BRC repeats and their impact on RAD51 disassembly, our investigation extends to larger BRCA2 truncations, offering unprecedented insights into the molecular determinants of RAD51 recognition. As mutations in the BRC repeats impair RAD51 recruitment and are associated with cancer, these results provide a valuable framework for interpreting pathogenic variants and guiding precision medicine therapies.
|
Oct 2026
|
|
I04-Macromolecular Crystallography
|
Michael H. N.
Meulendijks
,
Yun
Li
,
Frederik J.
Steiner
,
Rasmus
Klintrot
,
Clemens
Schulte
,
Seline
Roose
,
Alejandro
Yeste‐vázquez
,
Hans M.
Maric
,
Sven
Hennig
,
Felix M.
Paulussen
,
Ioana M.
Ilie
,
Tom N.
Grossmann
Diamond Proposal Number(s):
[34465]
Open Access
Abstract: Peptide-based inhibitors are promising tools to target challenging protein interfaces, yet improving their affinity and drug-like properties is still a major hurdle. This holds particularly true for β-sheet motifs with only limited strategies available to robustly stabilize their conformation. Previously, we reported linear β-hairpin peptide l12 with micromolar affinity for β-catenin, a central effector of aberrant Wnt signaling in cancer. Here, we show that a single N4V substitution markedly enhances binding, despite not directly contacting the protein surface as evidenced by obtained X-ray structures and molecular dynamics simulations. Notably, the substitution combines additively with head-to-tail cyclization yielding a peptide with strongly increased affinity. This mechanistic study presents structural and computational analyses revealing that the affinity improvements arise from solution-state preorganization and β-hairpin stabilization mediated by an altered intramolecular hydrogen bond network. Our findings highlight the critical role of conformational preorganization in peptide-protein recognition, demonstrating that optimizing solution-state properties can unlock substantial affinity gains that are not obvious from crystal structures alone.
|
Sep 2026
|
|
I04-Macromolecular Crystallography
|
Juan
Del Pozo
,
Elisabeth
Hennessy
,
Patrick
Schoepf
,
Kazuaki
Shibata
,
Kei
Akemoto
,
Naomi
Abe
,
Christopher
Agnew
,
Hiroki
Asakura
,
David J.
Bennett
,
Samantha A.
Burgess
,
Xiaomei
Chai
,
Gianni
Chessari
,
Philip J.
Day
,
Ruchia
Duggal
,
George M.
Giambasu
,
Christopher C. F.
Hamlett
,
Yuan
Jiang
,
Taiki
Kida
,
Toshiharu
Komori
,
Hitomi
Kondo
,
Brian M.
Lacey
,
Todd W.
Mayhood
,
Risako
Miura
,
Shinji
Mizuarai
,
Erik V.
Munsell
,
Marc
O’reilly
,
Barbara
Rath
,
David C.
Rees
,
Michael C.
Ryan
,
Takeshi
Sagara
,
Toshihiro
Sakamoto
,
Jordan
De Jesus Silva
,
Nicolas
Solban
,
Xuelei Sherry
Song
,
Tetsuya
Sugimoto
,
Miki
Terasaka
,
David G.
Twigg
,
Hiroyuki
Ueno
,
Kentaro
Wakayama
,
Zangwei
Xu
,
Tomohiro
Yamamoto
,
Alexander
Stoeck
,
Yongxin
Han
Diamond Proposal Number(s):
[27057]
Abstract: Current KRASG12C inhibitors mainly target the inactive GDP-bound state, but clinical efficacy is limited, and resistance mechanisms have been identified. We disclose novel covalent inhibitors that selectively target the active GTP-bound KRASG12C. Starting from a high-throughput screen, we identified a keto-indolizine scaffold featuring an aniline-derived acrylamide warhead that covalently binds Cys12 in the switch-II pocket of active KRASG12C. X-ray crystallography revealed key interactions of acrylamide with GMPPCP′s γ-phosphate, stabilizing the GTP state. We present medicinal chemistry efforts leading to the discovery of compound 17, which shows favorable oral bioavailability in preclinical species, exhibiting prolonged disruption of the KRAS-cRAF interaction and downstream ERK phosphorylation in vivo. In a KRASG12C-driven pancreatic cancer xenograft model (MIA PaCa-2), orally administered compound 17 achieved complete tumor regression for up to 45 days with good tolerability. This study establishes a novel class of KRASG12C inhibitors targeting the active GTP-bound state, which may have the potential to overcome some resistance mechanisms.
|
Sep 2026
|
|
I03-Macromolecular Crystallography
|
Diamond Proposal Number(s):
[34035]
Open Access
Abstract: The discovery of tubulysins sparked considerable interest due to their high cytotoxic activity against multidrug resistant tumors. Total synthesis of these complex natural products—peptidic metabolites from myxobacteria Archangium gephyra and Angiococcus disciformis—demonstrated the power of organic chemistry and paved the way for the development of simpler, more stable, and selective derivatives. Despite these significant achievements, tubulysins are not used as stand-alone drugs due to their toxic side effects. In this study, we outline the design, synthesis, and evaluation of photoswitchable tubulysin analogues, which could be starting points for development of photopharmacological therapies aimed at addressing the toxicity challenges associated with tubulysins. The cytotoxic activity of one of the key analogues was shown to be light-controllable. For the first time, we provide a comparative analysis of the crystal structures of both photoisomers of a diarylethene-containing compound complexed with target proteins. This comparison enables a mechanistic explanation for the experimentally observed differences in the target binding efficiency and respective activity between the two photoisomers of the photoswitchable tubulysin analogue.
|
Aug 2026
|
|